Printer Friendly

Johnson & Johnson.

1Q Revenues: $17.5 billion (+1%)

1Q Earnings: $4.9 billion (+1%)

Comments: Pharmaceutical sales were $8.2 billion in the quarter, up 6%, with domestic sales up 13% and international sales down 3%. REMICADE sales were $1.8 billion in the quarter, up 11%. SIMPONI/SIMPONI ARIA sales were $390 million, up 30%. STELARA sales were $735 million, up 34%. INVEGA SUSTENNA/XEPLION/TRINZA sales were $513 million, up 25%. New product sales growth was negatively impacted by lower sales of OLYSIO/SOVRIAD (simeprevir) down 86% to $32 million due to competitive Hep C entrants. Growth in new products include: IMBRUVICA with $261 million in sales, approved for certain B-cell malignancies; XARELTO (+29% to $567 million), an oral anticoagulant; and INVOKANA/INVOKAMET (+17% to $325 million), for the treatment of type 2 diabetes.

COPYRIGHT 2016 Rodman Publishing
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:FINANCIAL REPORTS
Publication:Contract Pharma
Date:Jun 1, 2016
Words:134
Previous Article:Charles River Laboratories.
Next Article:Aptar Pharma launches eDose Counter.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters